A vesicular seqestration to oxidative deamination shift in myocardial sympathetic nerves in Parkinson's disease

Journal of Neurochemistry

Volumn 131, Issue 2, 2014, Pages 219-228

  Goldestein, David S ^a   Sullivan, Patricia ^a   Holmes, Courtney ^a   Miller, Gary W ^b   Sharabi, Yehonatan ^c   Kopin, Irwin J ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b EMORY UNIVERSITY   (United States)

^c SHEBA MEDICAL CENTER   (Israel)

Author keywords

Catecholamines; Neurochemistry; Neurodegenera tive mechanisms; Parkinson's disease; Sympathetic nervous system

Indexed keywords

3,4 DIHYDROXYPHENYLACETIC ACID; 3,4 DIHYDROXYPHENYLETHYLENE GLYCOL; DOPAMINE; NORADRENALIN; SLC18A2 PROTEIN, MOUSE; VESICULAR MONOAMINE TRANSPORTER;

ADRENERGIC SYSTEM; ARTICLE; CATECHOLAMINE DEPLETION; CLINICAL ARTICLE; CONTROLLED STUDY; DEAMINATION; HEART; HEART MUSCLE; HUMAN; HUMAN TISSUE; METABOLITE; MOUSE; NIGRONEOSTRIATAL SYSTEM; NONHUMAN; OXIDATION; PARKINSON DISEASE; PUTAMEN; SYMPATHETIC NERVE; AGED; ANIMAL; DEFICIENCY; FEMALE; MALE; METABOLISM; OXIDATIVE STRESS; PATHOLOGY; PHYSIOLOGY; SYMPATHETIC NERVE CELL; SYNAPSE VESICLE; VERY ELDERLY;

MUS;

AGED; AGED, 80 AND OVER; ANIMALS; DEAMINATION; DOPAMINE; FEMALE; HUMANS; MALE; MICE; MYOCARDIUM; NOREPINEPHRINE; OXIDATIVE STRESS; PARKINSON DISEASE; SYMPATHETIC FIBERS, POSTGANGLIONIC; SYNAPTIC VESICLES; VESICULAR MONOAMINE TRANSPORT PROTEINS;

EID: 84918787112     PISSN: 00223042     EISSN: 14714159     Source Type: Journal    
DOI: 10.1111/jnc.12766     Document Type: Article

References (44)

1. Amino T., Orimo S., Takahashi A., Uchihara T. and Mizusawa H. (2005) Profound cardiac sympathetic denervation occurs in Parkinson disease. Brain Pathol. 15, 29-34.
2. Braak H., Ghebremedhin E., Rub U., Bratzke H. and Del Tredici K. (2004) Stages in the development of Parkinson's disease-related pathology. Cell Tissue Res. 318, 121-134.
3. Burke W. J., Kumar V. B., Pandey N. et al. (2008) Aggregation of alpha-synuclein by DOPAL, the monoamine oxidase metabolite of dopamine. Acta Neuropathol. 115, 193-203.
4. Caudle W. M., Ri chardson J. R., Wang M. Z. et al. (2007) Reduced vesicular storage of dopamine causes progressive nigrostriatal neurodegeneration. J. Neurosci. 27, 8138-8148.
5. Cotzias G. C. (1971) Levodopa in the t reatment of Parkinsonism. JAMA 218, 1903-1908.
6. Del Tredici K. and Braak H. (2012) Lewy pathology and neurodegeneration in premotor Parkinson's disease. Mov. Disord. 27, 597-607.
7. Del Tred ici K., Hawkes C. H., Ghebremedhin E. and Braak H. (2010) Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease. Acta Neuropathol. 119, 703-713.
8. Ehringer H. and Hornykiewicz O. (1960) Distribution of noradrenaline and dopamine (3-hydroxytyramine) in the human brain and their behavior in diseases of the extrapyramidal system. Wien. Klin. Wochenschr. 38, 1236-1239.
9. Eisenhofer G., Friberg P., Rundqvist B., Quyyumi A. A., Lambert G., Kaye D. M., Kopin I. J., Goldstein D. S. and Esler M. D. (1996a ) Cardiac sympathetic nerve function in congestive heart failure. Circulation 93, 1667-1676.
10. Eisenhofer G., Pacak K., Goldstein D. S. and McCarty R. (1996b ) Sympathetic nervous system activity is increased in aged 344 Fischer rats, in Stress: Molecular, Genetic and Neuro biological Advances (McCarty R., Aguilera G., Sabban E. and Kvetnansky R., eds), pp. 949-965. Gordon and Breach, New York.
11. Eisenhofer G., Kopin I. J. and Goldstein D. S. (2004) Catecholamine metabolism: a contemporary view with implications for physiology and medicine. Pharmacol. Rev. 56, 331-349.
12. Eldrup E., Richter A. E. and Christensen N. J. (1989) Dopa, norepinephrine, and dopamine in rat tissues: no effect of sympathectomy on muscle dopa. Am. J. Physiol. 256, E284-E287.
13. Fujishiro H., Frigerio R., Burnett M., Klos K. J., Josephs K. A., Delledonne A., Parisi J. E., Ahlskog J. E. and Dickson D. W. (2008) C ardiac sympathetic denervation correlates with clinical and pathologic stages of Parkinson's disease. Mov. Disord. 23, 1085-1092.
14. Gaugler M. N., Genc O., Bobela W. et al. (2012) Nigrostriatal overabundance of al pha-synuclein leads to decreased vesicle density and deficits in dopamine release that correlate with reduced motor activity. Acta Neuropathol. 123, 653-669.
15. Goldstein D. S. (2003) Dysautonomia in Parkinson's disease: neurocardiological abnormalities. Lancet Neurol. 2, 669-676.
16. Goldstein D. S. (2013) Concepts of scientific integrative medicine applied to the physiology and pathophysiology of catecholamine systems. Comp. Physiol. 3, 1569-1610.
17. Goldstein D. S., Cannon R. O., Quyyumi A., Chang P., Duncan M., Brush J. E., Jr. and Eisenhofer G. (1991) Regional extraction of circulating norepinephrine, DOPA, and dihydroxypheny lglycol in humans. J. Auton. Nerv. Syst. 34, 17-35.
18. Goldstein D. S., Holmes C., Li S. T., Bruce S., Metman L. V. and Cannon R. O., 3rd (2000) Cardiac sympathetic denervation in Parkinson disease. Ann. Intern. Med. 133, 338-347.
19. Goldstein D. S., Holmes C., Bentho O., Sato T., Moak J., Sharabi Y., Imrich R., Conant S. and Eldadah B. A. (2008) Biomarkers to detect central dopamine defic iency and distinguish Parkinson disease from multiple system atrophy. Parkinsonism Relat. Disord. 14, 600-607.
20. Goldstein D. S., Holmes C., Kopin I. J. and Sharabi Y. (2011) Intraneuronal vesicular uptake of catecholamines is decreased in patients with Lewy body diseases. J. Clin. Invest. 121, 3320-3330.
21. Goldstein D. S., Sullivan P., Cooney A., Jinsmaa Y., Sullivan R., Gross D. J., Holmes C., Kopin I. J. and Sharabi Y. (2012) Vesicular uptake blockade generates the toxic dopamine metabolite 3,4-dihydroxyphenylacetaldehyde in PC12 Cells: relevance to the pathogenesis of Parkinson disease. J. Neurochem. 123, 932-943.
22. Goldstei n D. S., Sullivan P., Holmes C., Miller G. W., Alter S., Strong R., Mash D. C., Kopin I. J. and Sharabi Y. (2013) Determinants of buildup of the toxic dopamine metabolite DOPAL in Parkinson's disease. J. Neurochem. 126, 591-603.
23. Holmes C., Eisenhofer G. and Goldstein D. S. (1994) Improved assay for plasma dihydroxyphenylacetic acid and other catechols using high-performance liquid chromatography with electrochemical detection. J. Chromatogr. B Biomed. Appl. 653, 131-138.
24. Holmes C., Whittaker N., Heredia-Moya J. and Goldstein D. S. (2010) Contamination of the norepinephrine prodrug droxidopa by dihydroxyphenylacetaldehyde. Clin. Chem. 56, 832-838.
25. Janezic S., Threlfell S., Dodson P. D. et al. (2013) Deficits in do paminergic transmission precede neuron loss and dysfunction in a new Parkinson model. Proc. Natl Acad. Sci. USA 110, E4016-E4025.
26. Jinsmaa Y., Sullivan P., Gross D., Cooney A., Sharabi Y. and Goldstein D. S. (2014) Divalent metal ions enhance DOPAL-induced oligomerization of alpha-synuclein. Neurosci. Lett. (in press).
27. Kawamura M.,Kopin I. J.,Kador P. F.,Sato S.,Tjurmina O.,Eisenhofer G. 1997) Effects of aldehyde/aldose reductase inhibition on neuronal metabolism of norepinephrine. J. Auton. Nerv. Syst. 66 145-148.
28. Kish S. J., Shannak K. and Hornykiewicz O. (1988) Uneven pattern of dopamine loss in the striatum of patients with idiopathic Parkinson's disease. Pathophysiologic and clinical implications. N. Engl. J. Med. 318, 876-880.
29. Kopin I. J. (19 85) Catecholamine metabolism: basic aspects and clinical significance. Pharmacol. Rev. 37, 333-364.
30. Kopin I. J. and Weise V. K. (1968) Effect of reserpine and metaraminol on excretion of homovanillic acid and 3-methoxy-4-hydroxyphenylglycol in the rat. Biochem. Pharmacol. 17, 1461-1464.
31. Li S. W., Lin T. S., Minteer S. and Burke W. J. (2001) 3,4-Dihydroxyphenylacetaldehyde and hydrogen peroxide generate a hydroxyl radical: possible role in Parkinson's disease pathogenesis. Brain Res. Mol. Brain Res. 93, 1-7.
32. Lotharius J. and Brundin P. (2002) Pathogenesis of Parkinson's diease: dopamine, vesicles, and [alpha]-synuclein. Nat. Rev. Neurosci. 3, 932-942.
33. Mattammal M. B., Haring J. H., Chung H. D., Raghu G. and Strong R. (1995) An endogenous dopaminergic neurotoxin: implication for Parkinson's disease. Neurodegeneration 4, 271-281.
34. Mooslehner K. A., Chan P. M., Xu W., Liu L., Smadja C., Humby T., Allen N. D., Wilkinson L. S. and Emson P. C. (2001) Mice with very low expression of the vesicular monoamin e transporter 2 gene survive into adulthood: potential mouse model for parkinsonism. Mol. Cell. Biol. 21, 5321-5331.
35. Mosharov E. V., Staal R. G., Bove J. et al. (2006) Alpha-synuclein overexpression increases cytosolic catecholamine concentration. J. Neurosci. 26, 9304-9311.
36. Orimo S., Uchihara T., Nakamura A., Mori F., Kakita A., Wakabayashi K. and Takahashi H. (2008) Axonal alpha-synuclein agg regates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease. Brain 131, 642-650.
37. Panneton W. M., Kumar V. B., Gan Q., Burke W. J. and Galvin J. E. (2010) The neurotoxicity of DOPAL: behavioral and stereological evidence for its role in Parkinson disease pathogenesis. PLoS ONE 5, e15251.
38. Raffel D. M., Koeppe R. A., Little R., Wang C. N., Liu S., Junck L., Heumann M. and Gilman S. (2006) PET measurement of cardiac and nigrostriatal denervation in parkinsonian syndromes. J. Nucl. Med. 47, 1769-1777.
39. Rees J. N., Florang V. R., Eckert L. L. and Doorn J. A. (2009) Protein reactivity of 3,4-dihydroxyphenylacetaldehyde, a toxic dopamine metabolite, is dependent on both the aldehyde and the catechol. Chem. Res. Toxicol. 22, 1256-1263.
40. Su Y., Duan J., Ying Z., Hou Y., Zhang Y., Wang R. and Deng Y. (2013) Increased vulnerability of parkin knock down PC12 cells to hydrogen peroxide toxicity: the role of salsolinol and NMsalsolinol. Neuroscience 233, 72-85.
41. Taylor T. N., Caudle W.M., Shepherd K. R., Noorian A., Jackson C. R., Iuvone P. M., Weinshenker D., Greene J. G. and Miller G. W. (2009) Nonmotor symptoms of Parkinson's disease revealed in an animal model with reduced monoamine storage cap acity. J. Neurosci. 29, 8103-8113.
42. Taylor T. N., Alter S. P., WangM., Goldstein D. S. and Miller G. W. (2014) Reduced vesicular storage of catecholamines causes progressive degeneration in the locus ceruleus. Neuropharmacology 76, A97-A105.
43. Volles M. J. and Lansbury P. T., Jr. (2002) V esicle permeabilization by protofibrillar alpha-synuclein is sensitive to Parkinson's diseaselinked mutations and occurs by a pore-like mechanism. Biochemistry 41, 4595-4602.
44. Wilson J. M., Levey A. I., Rajput A. et a l. (1996) Differential changes in neurochemical markers of striatal dopamine nerve terminals in idiopathic Parkinson's disease. Neurology 47, 718-726.